Skip to Content

About Us

Start-up Companies

The Office of Technology Commercialization (OTC) actively identifies platform-level technologies suitable for start-up company formation. These companies help create institutional value for the intellectual property derived from novel inventions made by MD Anderson researchers and faculty. Since 1987, OTC has been involved in the creation of 11 affiliated companies that have raised more than $300 million on the strength of MD Anderson technologies. Four portfolio companies listed on NASDAQ have raised more than $230 million and funded $25 million in sponsored research at MD Anderson. Listed below are companies based on MD Anderson technologies.

OTC welcomes inquiries and is pleased to provide information regarding start-up opportunities. Please contact us for additional information.

Portfolio Companies

Public Companies


Macrophage (now Antigenics)

  • Established in 1987
  • Development and commercialization of pharmaceutical products to treat cancer and infectious diseases. The following product is in clinical development:
  • Aroplatin for treatment of colorectal cancer

BioQuest (now AdventRx Pharmaceuticals)

  • Established 1996
  • Developing new technologies for anticancer and antiviral treatments that improve the performance of existing drugs and address significant problems such as drug resistance.

R-Gene (now Targeted Genetics)

  • Established 1994
  • Gene Therapy: E1a against Her2/neu overexpressing breast and cervical tumors.

Private Companies


ApoCell, Inc.

  • Established 2004
  • Biomarker discovery and development company

Castle Biosciences, Inc.   

  • Established 2008
  • Located in Friendswood, Texas
  • Focus on proprietary molecular diagnostic assays that assist oncologists in individual risk-stratification for orphan cancers; Occurrence rate <40,000/year.

DNATrix, Inc.   

  • Established 2008
  • Based in Houston, Texas
  • Developing a new generation of oncolytic technology designed to destroy cancer cells while leaving healthy cells unharmed.
  • Lead product, delta24RGD, is a next-generation adenovirus.

Fem.CadeT Taxol, L.L.C. (Partnered with Cell Therapeutics, Inc.)

  • Established 1998
  • Developing and commercializing water soluble paclitaxel cancer therapeutics

IDev Technologies, Inc.

  • Established 2000
  • Development of minimally invasive/interventional radiology devices.

BioPath Holdings, Inc.

  • Established 2001
  • Specialty pharmaceutical company focused on pre-clinical and clinical development of cancer therapeutics
  • Delivery solutions for therapeutic compounds including siRNA

Moleculin, LLC

  • Located in Houston, Texas
  • Specialty pharmaceutical company focused on the dermatologic market.

NanoSpectra Biosciences, Inc.

  • Established 2001
  • Nanotechnology for optical therapeutics

Nuvera Biosciences, Inc.

  • Established 2004
  • Developing novel molecular diagnostics that will significantly improve detection and treatment of cancer

Oridigm Corporation (now MediQuest Therapeutics, Inc.)

  • Established 1990
  • Development of novel therapeutic drugs based on chemically modified polyamines, a family of important multifunctional cellular molecules. The lead Oridigm program is targeted at cancer.

For More Information


© 2014 The University of Texas MD Anderson Cancer Center